255 related articles for article (PubMed ID: 25268193)
61. GATA1 and cooperating mutations in myeloid leukaemia of Down syndrome.
Garnett C; Cruz Hernandez D; Vyas P
IUBMB Life; 2020 Jan; 72(1):119-130. PubMed ID: 31769932
[TBL] [Abstract][Full Text] [Related]
62. A Case of Novel GATA-1 Mutation-positive Transient Abnormal Myelopoiesis With Life-threatening Complications in a Neonate With Down Syndrome.
Sah RR; Ray S; Bhatia P; Dhir SK; Totadri S; Kumar N; Kumar P
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e292-e295. PubMed ID: 31876781
[TBL] [Abstract][Full Text] [Related]
63. Generation of CHOPi-008-B, a euploid iPSC line from a patient with Trisomy 21 and a GATA1 mutation.
Takasaki K; Kumar SS; Gagne A; French DL; Chou ST
Stem Cell Res; 2023 Oct; 72():103198. PubMed ID: 37677872
[TBL] [Abstract][Full Text] [Related]
64. Transcription factor GATA-1 and Down syndrome leukemogenesis.
Muntean AG; Ge Y; Taub JW; Crispino JD
Leuk Lymphoma; 2006 Jun; 47(6):986-97. PubMed ID: 16840187
[TBL] [Abstract][Full Text] [Related]
65. Morphologic and GATA1 sequencing analysis of hematopoiesis in fetuses with trisomy 21.
Hoeller S; Bihl MP; Tzankov A; Chaffard R; Hirschmann P; Miny P; Kühne T; Bruder E
Hum Pathol; 2014 May; 45(5):1003-9. PubMed ID: 24746204
[TBL] [Abstract][Full Text] [Related]
66. Complete blood count differences in a cohort of Down syndrome neonates with transient abnormal myelopoiesis screened for GATA1 pathogenic variants.
Orozco-Vela M; Corona-Rivera A; Cruz-Osorio RM; Mendoza-Maldonado L; Márquez-Mora A; Barba-Barba CC; Peña-Padilla C; Baldomero-López A; Bobadilla-Morales L; Corona-Rivera JR
Am J Med Genet A; 2020 Sep; 182(9):2085-2093. PubMed ID: 32681702
[TBL] [Abstract][Full Text] [Related]
67. [GATA1 analysis in myeloproliferative disorders associated to trisomy 21].
Fuster Soler JL; Norton A; Galera Miñarro A; Bermúdez Cortés M; Llinares Riestra ME; Ortuño Giner F
An Pediatr (Barc); 2011 Jan; 74(1):31-7. PubMed ID: 20870473
[TBL] [Abstract][Full Text] [Related]
68. GATA1 mutations in myeloproliferative disorders: nomenclature standardization and review of the literature.
Splendore A; Magalhães IQ; Pombo-de-Oliveira MS
Hum Mutat; 2005 Oct; 26(4):390-2. PubMed ID: 16134163
[No Abstract] [Full Text] [Related]
69. Hemophagocytosis by leukemic megakaryoblasts in acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13);RBM15-MKL1.
Wiseman DH; Bonney DK; Wynn RF
J Pediatr Hematol Oncol; 2012 Oct; 34(7):576-80. PubMed ID: 22469944
[TBL] [Abstract][Full Text] [Related]
70. Integrated differential transcriptome maps of Acute Megakaryoblastic Leukemia (AMKL) in children with or without Down Syndrome (DS).
Pelleri MC; Piovesan A; Caracausi M; Berardi AC; Vitale L; Strippoli P
BMC Med Genomics; 2014 Dec; 7():63. PubMed ID: 25476127
[TBL] [Abstract][Full Text] [Related]
71. Transient leukemia in a newborn without Down syndrome: case report and review of the literature.
Rozen L; Huybrechts S; Dedeken L; Heijmans C; Dessars B; Heimann P; Lambert F; Noubouossie DF; Ferster A; Demulder A
Eur J Pediatr; 2014 Dec; 173(12):1643-7. PubMed ID: 24253371
[TBL] [Abstract][Full Text] [Related]
72. Telomerase and the benign and malignant megakaryoblastic leukemias of Down syndrome.
Holt SE; Brown EJ; Zipursky A
J Pediatr Hematol Oncol; 2002 Jan; 24(1):14-7. PubMed ID: 11902731
[TBL] [Abstract][Full Text] [Related]
73. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1.
Li Z; Godinho FJ; Klusmann JH; Garriga-Canut M; Yu C; Orkin SH
Nat Genet; 2005 Jun; 37(6):613-9. PubMed ID: 15895080
[TBL] [Abstract][Full Text] [Related]
74. [Myeloid proliferations related to Down syndrome].
Hasegawa D
Rinsho Ketsueki; 2019; 60(9):1299-1307. PubMed ID: 31597856
[TBL] [Abstract][Full Text] [Related]
75. [Congenital transient leukemia: a case report].
Li-Thiao-Te V; Bourges-Petit E; Capiod JC; Horle B; Micheli J; Morin G; Maingourd Y; Pautard B
Arch Pediatr; 2008 Jan; 15(1):33-6. PubMed ID: 18162385
[TBL] [Abstract][Full Text] [Related]
76. Contribution of GATA1 dysfunction to multi-step leukemogenesis.
Shimizu R; Yamamoto M
Cancer Sci; 2012 Dec; 103(12):2039-44. PubMed ID: 22937757
[TBL] [Abstract][Full Text] [Related]
77. Blast cell deficiency of CD11a as a marker of acute megakaryoblastic leukemia and transient myeloproliferative disease in children with and without Down syndrome.
Boztug H; Schumich A; Pötschger U; Mühlegger N; Kolenova A; Reinhardt K; Dworzak M
Cytometry B Clin Cytom; 2013; 84(6):370-8. PubMed ID: 23450818
[TBL] [Abstract][Full Text] [Related]
78. Hematological disorders in children with Down syndrome.
Triarico S; Trombatore G; Capozza MA; Romano A; Mastrangelo S; Attinà G; Maurizi P; Ruggiero A
Expert Rev Hematol; 2022 Feb; 15(2):127-135. PubMed ID: 35184659
[TBL] [Abstract][Full Text] [Related]
79. Chemokine levels predict progressive liver disease in Down syndrome patients with transient abnormal myelopoiesis.
Kinjo T; Inoue H; Kusuda T; Fujiyoshi J; Ochiai M; Takahata Y; Honjo S; Koga Y; Hara T; Ohga S
Pediatr Neonatol; 2019 Aug; 60(4):382-388. PubMed ID: 30314728
[TBL] [Abstract][Full Text] [Related]
80. Synergistic roles of DYRK1A and GATA1 in trisomy 21 megakaryopoiesis.
Sit YT; Takasaki K; An HH; Xiao Y; Hurtz C; Gearhart PA; Zhang Z; Gadue P; French DL; Chou ST
JCI Insight; 2023 Oct; 8(23):. PubMed ID: 37906251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
